The study will have 2 parts (Part A and Part B). Part A of this research study (the dose escalation phase) will test the safety and effectiveness of the different doses of ALKS 4230 (study drug) to find the one that is the safest and most effective. Part B of this study (the dose expansion phase) will use the safe dosing determined in Part A to see how effectively the combination of ALKS 4230 and pembrolizumab treats your solid tumors.LKS 4230 is an investigational (experimental) drug; this means that is has not been approved by the US Food and Drug Administration (FDA) to treat your disease. This is an open-label study which means that all subjects will be taking the active study drugs.You can be in the study for as long as it is clinically beneficial to you.
This study is for participants that have been diagnosed with clinically detectable stage III-IV high-risk Melanoma. The investigational drug in this study is pembrolizumab. The purpose of this study is to compare outcomes of receiving the study drug either before and after or only after surgery for your type of cancer. Participants can expect to be followed for up to 10 years after they register to the study.
This study is for patients that have been diagnosed with Merkle Cell Carcinoma. The investigational drug in this study is pembrolizumab. The purpose of this study is to compare the usual approach of post-surgery observation with or without radiation to using pembrolizumab with or without radiation after surgery. Participants can expect to be on this study for a total of 5 years.
This study is for patients that have been diagnosed with Merkel cell carcinoma. The investigational drug in this study is pembrolizumab. This study will compare any good and bad effects of using radiation along with an immunotherapy treatment [MK-3475 (pembrolizumab)] compared with MK-3475 (pembrolizumab) alone. Participants can expect to be in this study for up to 7 years.